$117 Million is the total value of Birchview Capital, LP's 52 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 5.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMY | Sell | BRISTOL-MYERS SQUIBB CO | $41,573,898 | -10.8% | 716,297 | -1.7% | 35.38% | +1.3% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $8,689,500 | +9.4% | 77,240 | -8.3% | 7.40% | +24.2% |
| BDSX | Buy | BIODESIX INC COM RST | $8,527,159 | +37.6% | 5,193,336 | +3.0% | 7.26% | +56.2% |
| PRTA | Buy | PROTHENA CORP PLC | $8,181,946 | -23.2% | 169,574 | +8.6% | 6.96% | -12.8% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $5,009,936 | -16.1% | 240,400 | -3.6% | 4.26% | -4.8% |
| QDEL | QUIDELORTHO CORP | $4,762,427 | -11.9% | 65,203 | 0.0% | 4.05% | +0.1% | |
| OVV | OVINTIV INC | $4,005,394 | +25.0% | 84,200 | 0.0% | 3.41% | +41.9% | |
| IMGN | IMMUNOGEN INC | $3,015,300 | -15.9% | 190,000 | 0.0% | 2.57% | -4.5% | |
| UTHR | Sell | UNITED THERAPEUTICS CORP | $2,484,570 | -25.0% | 11,000 | -26.7% | 2.12% | -14.8% |
| AZYO | ELUTIA INC | $2,366,913 | -39.4% | 1,655,184 | 0.0% | 2.01% | -31.2% | |
| HROW | HARROW HEALTH INC | $2,155,500 | -24.5% | 150,000 | 0.0% | 1.84% | -14.3% | |
| PHR | PHREESIA INC | $1,544,836 | -39.8% | 82,700 | 0.0% | 1.32% | -31.6% | |
| ALKS | ALKERMES PLC | $1,400,500 | -10.5% | 50,000 | 0.0% | 1.19% | +1.6% | |
| BLUE | Buy | BLUEBIRD BIO INC | $1,383,808 | +68.8% | 455,200 | +82.7% | 1.18% | +91.5% |
| CORT | CORCEPT THERAPEUTICS INC | $1,362,250 | +22.4% | 50,000 | 0.0% | 1.16% | +39.0% | |
| MASI | MASIMO CORP | $1,339,750 | -46.7% | 15,280 | 0.0% | 1.14% | -39.5% | |
| FHTX | FOGHORN THERAPEUTICS INC | $1,324,215 | -29.0% | 264,843 | 0.0% | 1.13% | -19.4% | |
| AXDX | Sell | ACCELERATE DIAGNOSTICS INC | $1,295,123 | -29.0% | 225,239 | -90.0% | 1.10% | -19.4% |
| INBX | INHIBRX INC | $1,292,721 | -29.3% | 70,448 | 0.0% | 1.10% | -19.8% | |
| ETRN | EQUITRANS MIDSTREAM CORPORATIO | $1,246,679 | -2.0% | 133,050 | 0.0% | 1.06% | +11.3% | |
| ATEC | ALPHATEC HOLDINGS INC | $1,037,600 | -27.9% | 80,000 | 0.0% | 0.88% | -18.1% | |
| VENTYX BIOSCIENCES INC | $916,872 | +5.9% | 26,400 | 0.0% | 0.78% | +20.2% | ||
| PXD | PIONEER NATURAL RESOURCES CO | $872,290 | +10.8% | 3,800 | 0.0% | 0.74% | +25.8% | |
| TXG | Buy | 10X GENOMICS INC | $866,250 | +29.3% | 21,000 | +75.0% | 0.74% | +46.8% |
| AXGN | Buy | AXOGEN INC | $865,000 | +136.9% | 173,000 | +332.5% | 0.74% | +168.6% |
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $766,255 | +46.9% | 571,832 | +96.3% | 0.65% | +66.8% |
| CYTK | CYTOKINETICS INC | $736,500 | -9.7% | 25,000 | 0.0% | 0.63% | +2.6% | |
| TVTX | Buy | TRAVERE THERAPEUTICS INC | $733,080 | +19.3% | 82,000 | +105.0% | 0.62% | +35.4% |
| Buy | DOCGO INC | $692,900 | -32.8% | 130,000 | +18.2% | 0.59% | -23.7% | |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $684,720 | -37.4% | 18,000 | +50.0% | 0.58% | -28.8% |
| PTGX | PROTAGONIST THERAPEUTICS INC | $633,840 | -39.6% | 38,000 | 0.0% | 0.54% | -31.5% | |
| SILK | Buy | SILK ROAD MEDICAL INC | $618,997 | -4.7% | 41,294 | +106.5% | 0.53% | +8.2% |
| PGNY | Buy | PROGYNY INC | $612,360 | +73.0% | 18,000 | +100.0% | 0.52% | +96.6% |
| KNSA | KINIKSA PHARMACEUTICALS LTD | $521,100 | +23.4% | 30,000 | 0.0% | 0.44% | +40.1% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $385,200 | +7.0% | 40,000 | 0.0% | 0.33% | +21.5% | |
| HALO | HALOZYME THERAPEUTICS INC | $382,000 | +5.9% | 10,000 | 0.0% | 0.32% | +20.4% | |
| XENE | XENON PHARMACEUTICALS INC | $341,600 | -11.3% | 10,000 | 0.0% | 0.29% | +0.7% | |
| FOLD | AMICUS THERAPEUTICS INC | $340,480 | -3.2% | 28,000 | 0.0% | 0.29% | +9.8% | |
| STOK | STOKE THERAPEUTICS INC | $334,900 | -62.9% | 85,000 | 0.0% | 0.28% | -57.9% | |
| SRPT | SAREPTA THERAPEUTICS INC | $303,050 | +5.9% | 2,500 | 0.0% | 0.26% | +20.0% | |
| ARVN | ARVINAS INC | $294,600 | -20.9% | 15,000 | 0.0% | 0.25% | -10.0% | |
| XNCR | XENCOR INC | $247,845 | -19.3% | 12,300 | 0.0% | 0.21% | -8.3% | |
| 2SEVENTY BIO INC | $234,545 | -61.3% | 59,833 | 0.0% | 0.20% | -55.9% | ||
| CGEM | CULLINAN ONCOLOGY INC | $227,282 | -15.9% | 25,114 | 0.0% | 0.19% | -4.9% | |
| KROS | KEROS THERAPEUTICS INC | $223,160 | -20.7% | 7,000 | 0.0% | 0.19% | -10.0% | |
| GOSS | Buy | GOSSAMER BIO INC | $174,128 | +46.4% | 209,088 | +111.0% | 0.15% | +66.3% |
| GTHX | Buy | G1 THERAPEUTICS INC | $172,800 | +73.5% | 120,000 | +200.0% | 0.15% | +96.0% |
| IFRX | INFLARX NV | $149,000 | -33.2% | 50,000 | 0.0% | 0.13% | -24.0% | |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $141,600 | +0.6% | 20,000 | 0.0% | 0.12% | +14.2% | |
| NKTR | NEKTAR THERAPEUTICS | $16,677 | +3.5% | 28,000 | 0.0% | 0.01% | +16.7% | |
| YTEN | YIELD10 BIOSCIENCE INC | $6,126 | -85.3% | 18,750 | 0.0% | 0.01% | -83.9% | |
| KDNY | Exit | CHINOOK THERAPEUTICS INC | $0 | – | -15,000 | -100.0% | -0.43% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -25,000 | -100.0% | -0.74% | – |
| SLNO | Exit | SOLENO THERAPEUTICS INC | $0 | – | -245,127 | -100.0% | -0.79% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACCELERATE DIAGNOSTICS INC | 36 | Q3 2023 | 34.6% |
| QUIDELORTHO CORP | 36 | Q3 2023 | 8.6% |
| MASIMO CORP | 36 | Q3 2023 | 2.2% |
| PIONEER NATURAL RESOURCES CO (PXD) | 36 | Q3 2023 | 0.7% |
| XENCOR INC | 35 | Q3 2023 | 0.4% |
| NEUROCRINE BIOSCIENCES INC | 33 | Q3 2023 | 7.4% |
| CORCEPT THERAPEUTICS INC | 32 | Q3 2023 | 1.2% |
| BIOGEN INC | 31 | Q2 2022 | 3.1% |
| CONTRAFECT CORP | 30 | Q3 2022 | 1.6% |
| YIELD10 BIOSCIENCE INC | 26 | Q3 2023 | 0.6% |
View Birchview Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SOLENO THERAPEUTICS INC | March 19, 2019 | 742,635 | 2.3% |
| YIELD10 BIOSCIENCE, INC. | December 29, 2017 | 186,079 | 2.2% |
| HANSEN MEDICAL INC | February 16, 2016 | ? | ? |
| METABOLIX, INC. | June 23, 2015 | 749,696 | 2.8% |
View Birchview Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3/A | 2024-02-20 |
| 4/A | 2024-02-20 |
| SC 13G/A | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-04-07 |
| 4 | 2023-03-27 |
| 3 | 2023-02-13 |
View Birchview Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.